Unibest

Pharmaceutical intermediates

Crizotinib Intermediates

3 pharmaceutical intermediates for Crizotinib. Indication: Primary cutaneous anaplastic large cell lymphoma; Anaplastic large cell lymphoma; Non-small cell lung cancer.

提交项目All intermediates

About Crizotinib

Originator
Pfizer Inc
Indication
Primary cutaneous anaplastic large cell lymphoma; Anaplastic large cell lymphoma; Non-small cell lung cancer
Approved Date
08/26/2011
DS/DP
03/01/2025

Available intermediates

3 intermediates currently listed for Crizotinib. Request specifications, documentation or a quotation for any item below.

Crizotinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
tert-Butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H- pyrazol-1-yl]piperidine-1-carboxylate877399-74-1//
[5-Bromo-3-[(1R)-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin -2- yl]amine877399-00-3//
2-amino-5-bromopyridin-3-ol39903-01-0//

Other programs under C

Cabozantinib S-malateCalcipotriolCalcitriolCamlipixantCanagliflozinCangrelor TetrasodiumCapivasertib Capmatinib Hydrochloride

Building toward Crizotinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →